Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study 3D (Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir) + RBV in GT1 TURQUOISE-I.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials Analysis of Resistance Associated Variants by HCV Genotype 1 subtypes 1a and.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

No HBV or HIV co-infection

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Roth D. Lancet 2015; Oct 6; 386: C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24.

LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.

Meeting the Global Challenge ~ International workshop on antiviral drug resistance.

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,

W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated.

Phase 3 Treatment Experienced

ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.

GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b

Phase 3 Treatment-Naïve and Treatment-Experienced

Design Randomisation* 1 : 1 Open-label W12

Failure to achieve SVR on No HBV or HIV co-infection

Resistance to HCV direct-acting antivirals: What should we know?

Design Randomisation* 1 : 1 Double blind W12

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

Resistance to Direct Acting Antiviral Therapy

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

HCV Care in Unique Patient Populations

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Phase 3 Treatment-Naïve and Treatment-Experienced

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Phase 3 Treatment-Naïve and Treatment-Experienced

Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.

New Agents, New Regimens, New Strategies

Virological tools to diagnose and monitor hepatitis C virus infection

Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in.

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Drug-resistant human immunodefiency virus

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Volume 155, Issue 5, Pages e2 (November 2018)

LDV/SOF ± RBV in genotype 3 or 6 – Phase 2

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 142, Issue 6, Pages (May 2012)

What Does the Future Hold and What Will It Mean for Patients?

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Phase 3 Treatment-Naïve and Treatment-Experienced

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

Presentation transcript:

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection

Disclosures

Acknowledgements

background

Background

Methods

Grazoprevir treatment regimens

Patient Demographics

Patients with GT1 NS3 RAVs Detected at the time of failure

Patients with GT1 NS3 RAVs Detected at the time of failure

Patients with GT1 NS5A RAVs Detected at the time of failure

Patients with GT1 NS5A RAVs Detected at the time of failure

Pre-existing NS3 and NS5A RAVs Persist >2 years post-treatment

Persistence of Treatment-emergent RAVs varies by target Region

The Profile of Pre-existing NS3 and NS5A RAVs is similar at virologic failure and at FW48

NS3 But noT NS5A Treatment-emergent RAVs show reversion to WT between virologic failure and FW48

Persistence of individual treatment-emergent ravs

Summary